Background: atrial fibrillation (AF) is a common cardiovascular morbidity, not least among elderly people, and is treated with different classes of cardiovascular pharmacotherapies. Hypothesis: cardiovascular drugs may have a different impact on survival in elderly patients with AF in primary health care. Methods: a cohort of 3,020 men and 3,749 women aged ≥75 and diagnosed with AF were selected from 75 primary care centres in Sweden. Laplace regression was used with years to death of the first 10% of the participants as the outcome. Independent variables were prescribed cardiovascular drugs. Regression models were adjusted for a propensity score comprising age, cardiovascular co-morbidities, socio-economic factors and other cardiovascular pharmacotherapies. Results: overall, mortality was 18.2%. The main finding of this study was survival increases associated with anticoagulants versus no treatment and versus antiplatelets of 1.95 years (95% confidence interval (CI) 1.43-2.48) and 0.78 years (95% CI 0.38-1.18), respectively, and survival increases associated with thiazides and calcium channel blockers of 0.81 years (95% CI 0.43-1.18) and 0.83 years (95% CI 0.47-1.18), respectively, in men and women together (results from sex-adjusted models). Conclusion: our findings suggest that anticoagulants, thiazides and calcium channel blockers may lead to longer survival in elderly patients with AF.
Introduction
Atrial fibrillation (AF) is one of the most common cardiovascular morbidities, with an estimated prevalence of 2.8% in people ≥20 years of age in Sweden [1] . In general, men develop AF on average 5 years earlier than women [2] and have a 1.5-fold greater risk of developing AF compared with women [3] . In contrast, women with AF have a higher risk of both stroke and all-cause mortality than men with AF [4] .
The annual risk of stroke increases steeply with age, from 1.5% in those aged 50-59 to 23 .5% in those aged 80-89 [3] , making stroke prevention in the elderly important. For this purpose, anticoagulant therapy is acknowledged as superior to antiplatelet therapy [5] . Antithrombotic therapy recommendations in AF are guided by stroke risk prediction by CHADS 2 or preferably by CHA 2 DS 2 VASc [6] . Age ≥75 scores one point in CHADS 2 and two points in CHA 2 DS 2 VASc, i.e. according to CHA 2 DS 2 VASc, all AF patients aged ≥75 should at least be considered for anticoagulant therapy if high risk of bleeding is absent. With regard to vascular and all-cause mortality in general, antiplatelets seem to be as effective as anticoagulants [7] . The effects of other cardiovascular drugs on mortality in the elderly have not been extensively studied.
A new type of regression analysis called Laplace regression allows life years gained or lost due to a certain type of pharmacotherapy to be calculated [8] . For example, the time until 10% of patients prescribed warfarin have died can be determined. We hypothesise that certain cardiovascular drugs may have an impact on survival in elderly patients with AF. Accordingly, the primary aim of this study was to study survival, in years, in AF patients aged ≥75 prescribed antiplatelets and anticoagulants. A further aim was to understand the effects of other cardiovascular drugs on mortality that are commonly prescribed to these patients.
Methods
Design The study used individual-level patient data from 75 primary health-care centers (PHCCs), 48 of which were located in Stockholm County. Individuals attending any of the participating PHCCs between 2001 and 2007 were included in the study. We used Extractor software (http://www.slso.sll.se/ SLPOtemplates/SLPOPage1____10400.aspx) to extract individual electronic patient records (EPRs). National identification numbers were replaced with new unique serial numbers to ensure anonymity. The EPR files were linked to a database constructed using the Total Population Register, the Inpatient Register and the Swedish Cause of Death Register, which collectively contain individual-level data on age, gender, education and hospital admissions for all residents registered in Sweden [9] . A new research database containing clinical data and information on socio-economic status of the 1,098,420 primary care-seeking individuals registered at the 75 PHCCs was created. Data from the Cause of Death Register, which have been shown to be 99.8% complete, were used for the follow-up [10] .
Study population
All persons diagnosed with AF and aged ≥75 at the time of AF diagnosis who attended one of the 75 PHCCs between 1 January 2001 and 31 December 2007 were included in this study. They were identified by the presence of the ICD-10 code for AF (I48) in their medical records. In total, 6,769 individuals (3,020 men and 3,749 women) were included.
Outcome variable
The outcome variable was time from AF diagnosis registration to death until 31 December 2007.
Pharmacotherapies
Drugs prescribed to individuals in the study population during the assessment period were recorded by Anatomic Therapeutic Chemical (ATC) classification, as described in detail elsewhere [11] . With regard to antithrombotic drugs (B01A), patients were divided into three groups: no treatment, antiplatelet treatment (B01AC), including acetylsalicylic acid (B01AC6 and B01AC30), and anticoagulant treatment (B01AA) (with or without antiplatelet treatment). Diuretic drugs (C03) were recorded as thiazides or related agents and were also registered when combined with loop diuretics (C03C), potassium-saving diuretics (C03D), including aldosterone antagonists (C03DA), or other drugs (C03A, C03B, C03E, C09B and C09DA). Furthermore, the following cardiovascular agents were recorded: heart-active drugs (C01), including digitalis (C01A) and specific anti-arrhythmic drugs (C01B: quinidine (C01BA01), disopyramide (C01BA03), propafenone (C01BC03), flecainide (C01BC04) and amiodarone (C01BD01)), beta blockers (C07), calcium channel blockers (C08) and RAS-blocking agents (C09). Lipid-lowering drugs (C10A), including statins (C10AA), and levothyroxine (H03A) were also recorded.
Demographic and socio-economic variables
Gender: male or female.
Age: individuals were divided into the following age groups: 75-79, 80-84 and ≥85 years. Individuals <75 years were excluded.
Educational level was categorised as ≤9 years ( partial or complete compulsory schooling), 10-12 years ( partial or complete secondary schooling) and >12 years (college and/ or university studies).
Marital status was classified as married, unmarried, divorced or widowed.
Co-morbidities
We identified the following cardiovascular co-morbidities among individuals in the study population from the EPRs: hypertension (I10-15), coronary heart disease (CHD; I20-25), congestive heart failure (CHF; I50 and I110), cerebrovascular diseases (CVDs; I60-69), including intracranial bleeding (I60-62), and diabetes mellitus (E10-14).
Statistical analyses
Differences in means and distributions of patients' characteristics between men and women were compared using Student's t-test, χ 2 analysis and Fisher's exact test. Laplace regression was used to calculate the difference in years until 10% of the participants prescribed pharmacotherapies versus those without these particular drugs died [12] . The 10th percentile was chosen, as the results of Laplace regression are more reliable if both exposed and unexposed individuals have a sufficient number of fatalities (events) during the follow-up. Confidence intervals (CIs) in the Laplace regression were calculated using a bootstrap technique. Each cardiovascular drug class was studied using Laplace regression models for men and women and sexadjusted Laplace regression models. The following cardiovascular drugs were studied: antithrombotic drugs (antiplatelets or anticoagulants), digitalis, diuretics (thiazides, loop diuretics and aldosterone antagonists), beta blockers, RAS-blocking agents, calcium channel blockers and statins. We also divided beta blockers into beta1-specific and non-specific beta blockers, RAS-blocking agents into angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), and calcium channel blockers into those with heart-and vessel-specific effects. We excluded specific anti-arrhythmic agents, potassium-saving agents other than aldosterone antagonists, and lipid-lowering agents other than statins due to their low prescription rates, which would have made the analyses problematic and difficult to interpret. It is generally known that socio-economic status may have an impact on morbidity, mortality and pharmacotherapy. Hence, adjustment was made for a unique propensity score for each cardiovascular drug class, thus making it possible to adjust for all other important factors or confounders for the specific drug class. The propensity score comprised clinical variables of importance, i.e. age group, cardiovascular co-morbidities (hypertension, CHD, CHF, CVDs and diabetes) and all other prescribed cardiovascular drugs, as well as socio-economic variables (educational level and marital status) [13] .
A P value of <0.01 for two-sided tests was considered statistically significant. This cut-off was used due to the multiple comparisons between men and women. A two-sided P value of <0.05 was considered statistically significant for variables in the Laplace regression analyses. However, due to the risk of type I errors, results significant for men, women and men and women combined were considered as significant, whereas results that were different for men and women were only considered significant when a significant interaction was present.
Results
The mean follow-up time was 3.4 years (standard deviation (SD) = 2.1), and results were calculated based on 22, 735 person-years at risk. Characteristics of the patients (n = 6,769) are shown separately for men (n = 3,020) and women (n = 3,749) in Table 1 . A total of 554 men (18.3%) and 681 women (18.2%) died during follow-up. Overall, men were significantly younger and had more education than women, while significantly more women were widowed than were men. Hypertension was more common among women.
Supplementary data, Table S2 available in Age and Ageing online show the rates of prescription of pharmacotherapies in men and women. Greater proportions of men were prescribed anticoagulants, specific anti-arrhythmic agents, RAS-blocking agents, ACE inhibitors, lipid-lowering drugs and statins. Greater proportions of women were prescribed antiplatelet agents, digitalis, all kinds of diuretics and beta1-selective agents.
Laplace regression models for men and women are shown in Table 2 . After adjustment for a propensity score including pharmacotherapies, significant longer survival for both men and women was associated with some pharmacological groups. This was true for anticoagulants versus no treatment and anticoagulants versus antiplatelets in men and women combined in sex-adjusted models: survival increase was 1.95 years (95% CI 1.43-2.48) for anticoagulants versus no treatment and 0.78 years (95% CI 0.38-1.18) for anticoagulants versus antiplatelets. Similar survival increases were seen for thiazides and calcium channel blockers in men and women combined in sex-adjusted models: survival increase versus no treatment was 0.81 years (95% CI 0.43-1. When considering results where a significant interaction by sex was found, survival was longer for women, but not men, for all RAS blockers versus no treatment (0.61 years (95% CI 0.05-1.18)) and for ACE inhibitors versus no treatment (0.66 years (95% CI 0.05-1.27)). Survival was shorter in men for aldosterone antagonists versus no treatment (−0.96 years (95% CI −1.32 to −0.60)).
Results not confirmed by significant results for men, women and men and women combined, or by a significant interaction by sex, included: (i) longer survival for men, and men and women combined, for antiplatelets versus no treatment; and (ii) for women and men and women combined for all beta blockers and heart-active and vessel-selective calcium channel blockers. Additionally, survival was longer: (i) for men only for non-selective beta blockers versus no treatment; and (ii) for women only for beta1-selective beta blockers versus no treatment. Statins were associated with increased survival only in the sex-adjusted model for women and men combined. Shorter survival among men was associated with prescribed loop diuretics. Mortality was analysed according to the different CHADS 2 and CHA 2 DS 2 VASc categories in Cox regression models (Table 3) . No significant differences between men and women using χ 2 analysis were found (data not shown in Table) .
Discussion
The main finding of this study was increased survival associated with anticoagulants versus no treatment and versus antiplatelets. Lower mortality was also seen in both men and women prescribed thiazides and calcium channel blockers. We found significant differences between men and women with regard to prescription of (i) aldosterone antagonists, with significantly shorter survival among men but not among women and (ii) RAS blockers in general and ACE inhibitors, with significantly longer survival among women but not among men.
One might have expected that all prescribed pharmacotherapies would potentially decrease mortality when prescribed to AF patients, and we found such effects for many, although not all, pharmaceutical groups. Anticoagulants were associated with longer survival, in relation to both no treatment and antiplatelet treatment, in line with the effect seen in stroke prevention. Contrary to this finding, loop diuretics and aldosterone antagonists were associated with increased mortality among men in the present study, but with a significant interaction by sex only for aldosterone antagonists. Being prescribed aldosterone antagonists might reflect more advanced CHF [14] . However, a gender difference is described for the aldosterone antagonist eplerenone, where women seem to benefit more than men [15] .
Both thiazides and calcium channel blockers in general were associated with longer survival. The general positive effect associated with calcium channel blockers is in accordance with a study on AF patients from the United Kingdom [16] , and the significant effect of vessel-selective calcium channel blockers in women but not in men is in accordance with a study on hypertensive patients [17] . As antihypertensive agents, there are conflicting results for calcium channel blockers, with one review showing an effect in reducing CHF [18] and another one an increased risk of incident CHF [19] . In relation to other antihypertensive agents, calcium channel blockers seem to be beneficial compared with beta blockers with regard to cardiovascular outcomes, compared with ACE inhibitors with regard to stroke and compared with ARBs with regard to stroke and myocardial infarction, but they do increase CHF events compared with diuretics, ACE inhibitors and ARBs [20] .
Interestingly, we found gender differences with regard to all RAS blockers and ACE inhibitors, with significantly longer survival among women but not among men, in line with earlier findings relating to the ACE inhibitor ramipril [15] .
With regard to the remaining findings, we recommend that they should be interpreted with caution. Regarding beta blockers, we found conflicting results, with longer survival with beta blockers in general and beta1-selective beta blockers among women, and with non-selective beta blockers in men. However, it has been shown that women with heart failure benefit more from beta blockers than men [21] . Furthermore, the reduced mortality associated with prescription of statins is in line with evidence of positive effects of statins [22] , including the elderly [23] . Statins have been shown to have anti-arrhythmic properties [24] , which could be relevant for patients with AF. However, we cannot exclude the possibility that the positive finding for survival was due to confounding by indication [25] , i.e. that severely ill patients are more rarely prescribed statins. The gender difference for loop diuretics associated with increased mortality among men was not confirmed by the interaction analysis.
Crude mortality was equal among women and men, as was previously shown in a Danish cohort of AF patients [26] . Women in this study were on average 1 year older than men (mean age of 82.4 versus 81.1 years) and could consequently be expected to have had a mortality rate around 25% lower than that in men (according to information from Statistics Sweden). We found no association between CHADS 2 or CHA 2 DS 2 VASc score and mortality, in contrast to an earlier Swedish study in which CHADS 2 was associated with increased mortality after stroke [27] . The likely reason for the lack of an association is tighter risk factor control and pharmacotherapy in individuals with multiple diagnoses.
Women accounted for 54.4% of all AF patients above 75 years of age in our study, in agreement with the findings of a study of all AF patients in Stockholm County, in which the proportion of females was 55.4% [1] . In a study from Germany, women accounted for 47% of patients [28] . We can only conclude that there are gender differences between different countries in the prevalence of AF among people aged 75 years or older.
Limitations
A limitation of this study was the sample size, which prevented us from detecting small differences, even though the analyses included almost 23,000 person-years at risk. Since this was an observational study of the association between prescription of drugs and mortality, the findings may have been subject to confounding by indication [25] . Moreover, with Laplace regression, only the 95% CIs are given, with the risk of type I statistical errors when performing multiple comparisons. To reduce these errors, we considered results that were similar in all categories (in men, women, and men and women combined) significant; when results were different in men and women, we considered them significant only if a significant interaction by sex was present. Furthermore, drugs prescribed by other caregivers, i.e. from hospitals or specialist open care, were not included in the patient records, which may have weakened the associations between prescription of certain medications and mortality in this study. We did not have access to doses of the prescribed drugs. We had no access to the blood pressure levels. Additionally, severity of CHF (according to New York Heart Association Class) and CHD (Canadian Cardiovascular Society Class) were not classified in the patient records. Moreover, AF could not be classified as paroxysmal, persistent or permanent and heart rhythm could not be classified as sinus rhythm or fibrillation rhythm.
Strengths
A major strength of this study was that we were able to link clinical data from individual EPRs to data from national demographic and socio-economic registers with <1% of information missing. In addition, an earlier study of the diagnoses recorded in the EPRs showed that <2% of all diagnoses per individual were missing [29] . While many previous followup studies of AF have used hospital data, the current study used data from primary care, which may better reflect the risks associated with AF in society. Moreover, randomised controlled trials often exclude individuals with co-morbidities, such as AF patients with concomitant diabetes and CHF. In the current study, we had the possibility to include these patients in the analyses, which means that the findings are more representative of the variety of patients encountered in clinical practice today. The use of a propensity score with co-variates relevant to mortality as the outcome was an additional strength of this study as it enabled adjustment with a low risk of over-fitting regression models [30] .
Conclusion
Anticoagulants had a positive effect on mortality in both men and women in the present study, which confirms the superiority of anticoagulants over antiplatelets in reducing mortality in elderly AF patients. Our findings of longer survival associated with thiazides and calcium channel blockers also suggest that these drugs may have positive effects in the elderly. The gender differences regarding the effects of RAS blockers and especially ACE inhibitors warrant further studies. Additional studies focusing on mortality in elderly AF patients that complement our observational findings are needed.
Key points
• Information on survival of elderly patients with AF and contributions of different classes of drugs is scarce.
• We used Laplace regression models adjusted for propensity scores to assess this.
• Anticoagulants, thiazides and calcium channel blockers were associated with increased survival among both men and women.
